PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-0.07%
Revenue decline while Drug Manufacturers - Specialty & Generic median is -0.07%. Seth Klarman would investigate if market share loss is temporary.
-34.65%
Cost reduction while Drug Manufacturers - Specialty & Generic median is -10.71%. Seth Klarman would investigate competitive advantage potential.
822.03%
Gross profit growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.91%. Joel Greenblatt would investigate competitive advantages.
822.56%
Margin expansion exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.67%. Joel Greenblatt would investigate competitive advantages.
207.41%
R&D growth while Drug Manufacturers - Specialty & Generic reduces spending. Peter Lynch would examine strategic differences.
-2.34%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
-17.12%
Marketing expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
-21.03%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-11.69%
Operating expenses reduction while Drug Manufacturers - Specialty & Generic median is -7.41%. Seth Klarman would investigate advantages.
-26.23%
Total costs reduction while Drug Manufacturers - Specialty & Generic median is -10.26%. Seth Klarman would investigate advantages.
-74.43%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
10.45%
D&A growth while Drug Manufacturers - Specialty & Generic reduces D&A. Peter Lynch would examine asset strategy.
70.35%
EBITDA growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 29.28%. Joel Greenblatt would investigate advantages.
-99.75%
EBITDA margin decline while Drug Manufacturers - Specialty & Generic median is 11.90%. Seth Klarman would investigate causes.
-112.41%
Operating income decline while Drug Manufacturers - Specialty & Generic median is 21.34%. Seth Klarman would investigate causes.
-112.42%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is 14.95%. Seth Klarman would investigate causes.
-608.08%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 17.77%. Seth Klarman would investigate advantages.
87.31%
Pre-tax income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 45.00%. Joel Greenblatt would investigate advantages.
87.30%
Pre-tax margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 43.28%. Joel Greenblatt would investigate advantages.
289.61%
Tax expense growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 40.45%. Jim Chanos would check for issues.
85.63%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 43.90%. Joel Greenblatt would investigate advantages.
85.62%
Net margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 26.29%. Joel Greenblatt would investigate advantages.
86.67%
EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 44.19%. Joel Greenblatt would investigate advantages.
87.78%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 44.24%. Joel Greenblatt would investigate advantages.
11.12%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.01%. Jim Chanos would check for issues.
13.10%
Diluted share reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.03%. Jim Chanos would check for issues.